Stock Comparison

NVO vs UNH

Novo Nordisk A/S vs UnitedHealth Group Inc

Who's the better investment? Let's break it down.

The Verdict

NVO takes this one.

This one's close — only 1.0 points separating them. NVO wins by a hair, but both deserve a closer look.

Winner

NVO

Novo Nordisk A/S

1.3

out of 10

Distressed

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Want to compare any two stocks?

Valuation

NVO

Metric

UNH

$1.3T

Market Cap

$365.5B

10.6

P/E Ratio

Lower may indicate better value

30.3

11.9

Forward P/E

18.2

6.3

Price/Book

6.4

7.7

EV/EBITDA

16.8

Profitability & Growth

NVO

Metric

UNH

37.2%

Profit Margin

2.7%

81.8%

Gross Margin

18.5%

45.3%

Operating Margin

4.1%

66.4%

Return on Equity

12.4%

23.3%

Return on Assets

3.9%

8.1%

Revenue Growth

9.7%

$27.41

EPS

$13.24

Financial Health

NVO

Metric

UNH

0.7

Debt-to-Equity

Lower = less leverage

0.8

Current Ratio

Above 1.0 is healthy

0.9

1.9

Beta

Lower = less volatile

0.6

4.0%

Dividend Yield

2.3%

Risk Comparison

NVO

Overall

Moderate

Financial

Low

Market

Low

Competitive

High

Execution

Medium

Regulatory

Medium

What Could Go Wrong

The biggest risk is sustained and aggressive competition from Eli Lilly and other emerging players in the GLP-1 market, which could continue to pressure realized prices. As evidenced by the Q1 2026 re...

Red Flags

🚩Adjusted sales decline of 4% YoY in Q1 2026 due to lower realized prices, despite strong reported gr...
🚩Adjusted operating profit decline of 6% YoY in Q1 2026, indicating margin compression.
🚩Reliance on the GLP-1 franchise for a significant portion of revenue, making it vulnerable to compet...

UNH

Overall

Moderate

Financial

Low

Market

Medium

Competitive

Low

Execution

Low

Regulatory

High

What Could Go Wrong

The ongoing DOJ criminal and civil investigation, if it leads to significant penalties, forced divestitures, or operational restrictions, could severely impact Optum's growth trajectory and UNH's over...

Red Flags

🚩DOJ criminal and civil investigation: Presents an unquantified but potentially significant regulator...
🚩Reported membership contracting by 1.3 million in 2026 (from secondary source): If verified in futur...
🚩Very low insider ownership (0.28%): While common for mega-caps, it suggests less direct alignment wi...

Competitive Moat

NVO

Rating

🛡️ Wide

Trend

➡️ Stable, but facing erosion pressure

Intangible Assets (Patents, Brand Power)Cost Advantages (Scale in manufacturing and R&D)Switching Costs (Chronic medication adherence)

UNH

Rating

🛡️ Wide

Trend

➡️ Stable to Expanding

Efficient ScaleSwitching CostsIntangible Assets/IP (data, analytics, proprietary care models)Brand Power

Investment Thesis

NVO1.3/10

If Novo Nordisk successfully defends its market leadership in the rapidly expanding GLP-1 and obesity markets through continuous innovation, expanded indications, and strategic pricing, then it can sustain double-digit reported revenue growth and gradually improve adjusted profitability, supporting modest share price appreciation. This is bullish for long-term holders seeking stable growth, but it...

Full NVO Analysis

UNH0.3/10

If Optum continues to expand its health services and technology footprint at high-single-digit to low-double-digit rates, while UnitedHealthcare maintains stable profitability and manages its medical loss ratio, then UNH will deliver consistent EPS growth (high-single digits) and dividend increases. This makes UNH a reliable compounder for long-term capital appreciation and income, not a high-grow...

Full UNH Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

NVO1.3/10

Novo Nordisk (NVO) is a pharmaceutical powerhouse, commanding leadership in the diabetes and obesity markets, fueled by its dominant GLP-1 franchise. The Q1 2026 results show strong reported sales growth of 32% YoY at CER, and the company raised its 2026 outlook, reflecting robust demand. However, a critical red flag for 10x growth potential is the explicit *4% decline in adjusted sales due to lower realized prices* and a *6% decline in adjusted operating profit* in Q1 2026. This confirms intens...

Full NVO Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company capable of 10x growth within 3-5 years. Its immense scale, market maturity, and regulatory landscap...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.